Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01002248 | Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients | terminated | Phase 3 | 135 | AEterna ZentarisINDUSTRY | 9 | Feb 9, 2018 | clinicaltrials |
| NCT02354313 | Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients(MCL0208) | unknown | Phase 3 | 300 | Fondazione Italiana Linfomi - ETSOTHER | 2 | Feb 9, 2018 |
| clinicaltrials |
| NCT00784537 | High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients(HD0801) | completed | Phase 2 / Phase 3 | 520 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Feb 8, 2018 | clinicaltrials |
| NCT00877006 | Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study | completed | Phase 3 | 447 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 7 | Feb 5, 2018 | clinicaltrials |
| NCT01724021 | A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a | completed | Phase 3 | 743 | Hoffmann-La RocheINDUSTRY | 32 | Jan 23, 2018 | clinicaltrials |
| NCT00891384 | Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma | completed | Phase 3 | 194 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT01646021 | Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy | completed | Phase 3 | 280 | Janssen Research & Development, LLCINDUSTRY | 21 | Jan 19, 2018 | clinicaltrials |
| NCT03402295 | Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation(GBRAM003r) | completed | Phase 3 | 311 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 0 | Jan 18, 2018 | clinicaltrials |
| NCT00004874 | Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | terminated | Phase 3 | 31 | University of NebraskaOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT00562965 | Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL) | terminated | Phase 3 | 29 | PfizerINDUSTRY | 14 | Jan 9, 2018 | clinicaltrials |
| NCT03391739 | CART-19 Cells For R/R B-ALL(CCFRRBA) | unknown | Phase 2 / Phase 3 | 20 | Fujian Medical UniversityOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT02858258 | ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma | unknown | Phase 3 | 870 | Prof. Dr. M. Dreyling (co-chairman)OTHER | 5 | Dec 19, 2017 | clinicaltrials |
| NCT01722487 | Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL | completed | Phase 3 | 269 | Pharmacyclics LLC.INDUSTRY | 16 | Nov 30, 2017 | clinicaltrials |
| NCT00083915 | DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation | completed | Phase 3 | 97 | University of ArkansasOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00574080 | UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide | terminated | Phase 3 | 20 | University of ArkansasOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00657553 | Preemptive Strike With Bortezomib in Multiple Myeloma Patients(2007-77) | terminated | Phase 3 | 10 | University of ArkansasOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00310167 | Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma(FoRT) | completed | Phase 3 | 614 | University College, LondonOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT01852435 | R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B | unknown | Phase 3 | 648 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT02419118 | "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "(DARA) | completed | Phase 2 / Phase 3 | 4 | Vejle HospitalOTHER | 1 | Nov 7, 2017 | clinicaltrials |
| NCT01701232 | Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma | completed | Phase 3 | 174 | BiocadINDUSTRY | 5 | Nov 6, 2017 | clinicaltrials |
| NCT00056160 | CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 353 | CelgeneINDUSTRY | 2 | Oct 19, 2017 | clinicaltrials |
| NCT00424047 | A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 351 | CelgeneINDUSTRY | 15 | Oct 19, 2017 | clinicaltrials |
| NCT03229616 | BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 122 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT01649856 | A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma | completed | Phase 3 | 572 | Hoffmann-La RocheINDUSTRY | 27 | Oct 11, 2017 | clinicaltrials |
| NCT01916252 | Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old(GEM2012MENOS65) | completed | Phase 3 | 460 | PETHEMA FoundationOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT02248428 | Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma(CTd) | unknown | Phase 3 | 130 | Jinling Hospital, ChinaOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT00516503 | Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer | completed | Phase 3 | 208 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT01144364 | A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL) | completed | Phase 3 | 234 | Hoffmann-La RocheINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT01500083 | Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia(BENDACT) | completed | Phase 3 | 90 | Lundbeck Canada Inc.INDUSTRY | 1 | Aug 14, 2017 | clinicaltrials |
| NCT00355199 | Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL. | completed | Phase 3 | 246 | Gruppo Italiano Terapie Innovative nei LinfomiOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT03016000 | Thalidomide Maintenance Treatment in DLBCL | unknown | Phase 3 | 226 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 28, 2017 | clinicaltrials |
| NCT03018626 | R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL | unknown | Phase 3 | 402 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 28, 2017 | clinicaltrials |
| NCT00714259 | Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies | terminated | Phase 2 / Phase 3 | 5 | University of Alabama at BirminghamOTHER | 1 | Jul 24, 2017 | clinicaltrials |
| NCT00801281 | First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.(PLRG4) | completed | Phase 3 | 250 | Polish Lymphoma Research GroupNETWORK | 1 | Jul 17, 2017 | clinicaltrials |
| NCT02871869 | Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma | unknown | Phase 2 / Phase 3 | 316 | Xinjiang Medical UniversityOTHER | 1 | Jul 17, 2017 | clinicaltrials |
| NCT00790036 | Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy(PILLAR2) | completed | Phase 3 | 742 | Novartis PharmaceuticalsINDUSTRY | 34 | Jul 12, 2017 | clinicaltrials |
| NCT00075478 | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | completed | Phase 3 | 87 | Fred Hutchinson Cancer CenterOTHER | 3 | May 15, 2017 | clinicaltrials |
| NCT00719472 | A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)(RATE) | completed | Phase 3 | 451 | Genentech, Inc.INDUSTRY | 0 | May 15, 2017 | clinicaltrials |
| NCT03151044 | R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL | unknown | Phase 3 | 408 | FENG Ji-fengOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT00324324 | Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant | terminated | Phase 3 | 240 | OHSU Knight Cancer InstituteOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT00554164 | Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas(PETAL) | completed | Phase 3 | 1,073 | University Hospital, EssenOTHER | 1 | May 5, 2017 | clinicaltrials |
| NCT01302392 | A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma(FOCUS) | completed | Phase 3 | 315 | AmgenINDUSTRY | 19 | May 2, 2017 | clinicaltrials |
| NCT03123718 | High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL | unknown | Phase 3 | 205 | Chonnam National University HospitalOTHER | 1 | Apr 24, 2017 | clinicaltrials |
| NCT00025259 | Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease | completed | Phase 3 | 1,734 | Children's Oncology GroupNETWORK | 7 | Apr 12, 2017 | clinicaltrials |
| NCT00097981 | A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 3 | 225 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00732641 | Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7) | completed | Phase 3 | 244 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 4, 2017 | clinicaltrials |
| NCT00140582 | Primary Rituximab and Maintenance | completed | Phase 3 | 1,217 | Lymphoma Study AssociationOTHER | 12 | Mar 13, 2017 | clinicaltrials |
| NCT01277016 | A Trial for Systemic Light-chain (AL) Amyloidosis(EMN-03) | completed | Phase 3 | 110 | European Myeloma Network B.V.NETWORK | 1 | Mar 10, 2017 | clinicaltrials |
| NCT00209209 | Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL(MCLelderly) | unknown | Phase 3 | 570 | European Mantle Cell Lymphoma NetworkOTHER | 7 | Mar 7, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Feb 9, 2018source: clinicaltrials